Impact of Vertigoheel® on Patients Suffering From Bilateral Vestibulopathy and Functional Dizziness

Study Results

Results available

Outcome measurements, participant flow, baseline characteristics, and adverse events have been published for this study.

View full results

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Total Enrollment

62 participants

Study Classification

OBSERVATIONAL

Study Start Date

2021-11-29

Study Completion Date

2022-12-05

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

In this study the researcher observe how vertigo symptoms change during two months of treatment with the natural medicinal product Vertigoheel©. Adult patients suffering from vertigo symptoms can participate if they are diagnosed with bilateral vestibulopathy (BVP) or functional dizziness (FD) and assigned to Vertigoheel treatment. Participating patients receive an examination at study start and after 2 months of Vertigoheel treatment. The study focuses on patient reported outcomes assessed by questionnaires.

Vertigo symptoms are assessed by the Dizziness Handicap Inventory questionnaire. Patients' quality of life is assessed by a questionnaire. Body sway is assessed by static posturography. FD patients are additionally tested for depressive and anxiety symptoms by questionnaires. BVP patients are additionally tested for vestibular function by video head impulse test and caloric testing. Adverse events and other observations related to safety (physical examination and vital signs) are evaluated.

Vertigo is a common symptom with significant adverse effects on patients' quality of life. Regardless of the exact cause of vertigo attacks, it is important to reduce the frequency, intensity, and duration of vertigo attacks with an effective medication that has no or minimal adverse effect. Vertigoheel®, a natural medicinal product consisting of four ponderable active ingredients, is approved in Germany as treatment for vertigo of various origins. However, no systematic data are available for Vertigoheel® regarding patient-reported outcomes in BVP and FD as the most accepted endpoint in vertigo studies.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

BPPV Treatment in Biaxial Rotational Chair

NCT01905800

Benign Paroxysmal Positional Vertigo

COMPLETED NA

Comparison of EM and SM+ Maneuvers in Patients With BPPV

NCT05853328

BPPV

COMPLETED NA

Treatment of Posterior Canal Type of Benign Paroxysmal Positional Vertigo

NCT01822002

Benign Paroxysmal Positional Vertigo (BPPV)

UNKNOWN NA

Treatment of Apogeotropic Horizontal Canal Benign Paroxysmal Positional Vertigo

NCT02046980

Benign Paroxysmal Positional Vertigo

COMPLETED PHASE2

Effects of a Vestibular Rehabilitation Maneuver

NCT01080430

Vertigo

COMPLETED NA

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Vertigo Functional Dizziness Bilateral Vestibulopathy

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Observational Model Type

CASE_ONLY

Study Time Perspective

PROSPECTIVE

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Treatment with Vertigoheel® has been chosen by the physician independently of including the patient in this non-interventional study.
* Bilateral vestibulopathy or functional dizziness according to the current diagnostic criteria of the Bárány Society
* Symptoms for \> 3 months of moderate to severe intensity according to the dizziness handicap inventory \[0 (minimum score) -100 (maximum score)\] between 30 to 90 points.
* ≥18 years of age
* Legally competent male or female outpatient.
* Signed informed consent.
* Not pregnant (as proven by negative pregnancy test in case of woman of childbearing potential before first study drug administration) or breast-feeding.

Exclusion Criteria

* Having taken within the last 2 months or currently taking Vertigoheel®.
* Debilitating acute or chronic illness (i.e. psychiatric illnesses).
* History of sensitivity to any component of the study drug under observation.
* Unwilling or unable to comply with all the requirements of the study protocol.
* Any relationship of dependence with the sponsor or with the investigator.

Minimum Eligible Age

18 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No